On Wednesday, RBC Capital Markets updated its outlook on shares of Ligand Pharmaceuticals (NASDAQ:LGND), raising the price target to $143 from $141 while maintaining an Outperform rating on the stock. Currently trading at $118.60, Ligand has demonstrated remarkable momentum with a 66% gain year-to-date.
The adjustment follows Ligand Pharma's Investor Day held in Boston, where the company's management presented its financial guidance for 2025. The forecasts provided by management indicated that the mid-point of their projected ranges for total revenue and adjusted core earnings per share (EPS) are approximately 4% and 2% higher than the consensus estimates, respectively.
According to InvestingPro, analyst targets for the stock range from $125 to $157, suggesting potential upside from current levels.
Ligand Pharma's management anticipates a compound annual growth rate (CAGR) of about 22% in royalty receipts and projects that by 2029, royalty receipts will reach around $285 million. This projection surpasses the RBC Capital Markets estimate, which was approximately $257 million, not accounting for any potential future acquisitions.
The positive outlook is based on the expected growth of royalty receipts, a key revenue stream for the company. The company's strong financial position is evident from its balance sheet, with InvestingPro data showing more cash than debt and a robust current ratio of 12.49x, indicating excellent liquidity.
The firm's analysts have revised their financial estimates for Ligand Pharma to align with the newly announced guidance. This revision also takes into account the updated consensus revenue forecasts for the underlying drugs, as reported by Visible Alpha, a financial data analytics provider.
The incorporation of these revised forecasts has led to the slight increase in the price target for Ligand Pharma's shares. The company maintains a strong financial health score of "GREAT" on InvestingPro, which offers comprehensive analysis including 12+ additional key insights about the company's valuation and growth prospects.
Ligand Pharma's Investor Day provided investors with a comprehensive view of the company's strategic direction and financial expectations for the coming years. The management's guidance reflects confidence in the company's growth trajectory, especially in terms of royalty income.
RBC Capital Markets' updated price target suggests a modest optimism in Ligand Pharma's stock, signaling a potential upside based on the company's financial prospects and strategic initiatives. The Outperform rating remains unchanged, indicating that the firm continues to view the stock favorably in comparison to the broader market.
In other recent news, Ligand Pharmaceuticals has reported robust financial growth. The company anticipates a 17% increase in revenue growth for fiscal year 2025, with projections ranging from $180 million to $200 million. This growth is expected to be driven by twelve commercial-stage programs and a late-stage pipeline. Ligand also reported a 58% increase in total revenue year-over-year for the third quarter of 2024.
Oppenheimer has maintained its Outperform rating on Ligand and raised the price target to $150.00, while RBC Capital Markets has upgraded its price target on Ligand shares to $141.00, maintaining an Outperform rating. These upgrades reflect recent developments and the company's strong financial position.
Ligand's 2025 financial outlook includes royalty revenue between $135 million and $140 million, Captisol sales between $35 million and $40 million, and contract revenue in the range of $10 million to $20 million. The company also expects core adjusted earnings per diluted share to be between $6.00 and $6.25.
Ligand is actively evaluating 25 potential investments, each with an average targeted investment size of $30 million to $40 million. These recent developments reflect Ligand's robust financial health and strategic market approach, with long-term royalty revenue growth projected at a compound annual rate of over 22%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.